Bass Gets PTAB Review Of Fresenius Diprivan Patent
Hedge fund manager Kyle Bass has convinced the Patent Trial and Appeal Board to review a patent covering Fresenius' anesthetic agent Diprivan, while the board said Wednesday it was fine that...To view the full article, register now.
Already a subscriber? Click here to view full article